Abstract
Lung adenocarcinomas show intratumoral heterogeneity which has significant impact on the selection of targeted therapy. Multiple molecular sub-clones coexist within an individual tumour which determine recurrence and metastasis formation which is often under-evaluated in a single-site needle biopsy. Our case report demonstrates this intriguing phenomenon and the importance of multiple-site molecular testing to determine the dominant molecular alteration, and initiating the appropriate targeted therapy for better prognosis. Molecular testing from accessible metastatic sites in lung cancer is recommended for a complete assessment of prognosis and therapeutic options in recurrent and metastatic disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
